Ongoing research and clinical trials are crucial to further elucidate the efficacy and safety of IL-17A inhibitors, potentially paving the way for novel therapeutic strategies that integrate the management of psoriasis and cardiovascular risk. Here, IL17A is linked to psoriasis.